ImmunityBio (IBRX) announced that ANKTIVA is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom: In combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease; and In combination with an immune checkpoint inhibitor for the treatment of adult patients with metastatic non-small cell lung cancer, as authorized by the Saudi Food and Drug Authority. ANKTIVA is being distributed through ImmunityBio’s partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, with support from the company’s wholly owned subsidiary in Saudi Arabia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio call volume above normal and directionally bullish
- ImmunityBio Faces Lawsuit Over Anktiva Promotion After FDA Warning Letter
- ImmunityBio reports preliminary Q1 net product revenue $44.2M
- ImmunityBio Addresses FDA Warning on ANKTIVA Promotion
- ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance